Jeremy Bender Sells 15,894 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 15,894 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the completion of the sale, the chief executive officer owned 177,165 shares of the company’s stock, valued at $1,578,540.15. This represents a 8.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Day One Biopharmaceuticals Stock Down 3.1%

NASDAQ DAWN traded down $0.27 during trading on Tuesday, reaching $8.57. 1,531,756 shares of the stock traded hands, compared to its average volume of 1,496,830. The firm has a market cap of $879.97 million, a price-to-earnings ratio of -5.64 and a beta of -1.25. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $14.46. The stock’s 50-day moving average price is $7.63 and its 200 day moving average price is $7.05.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company had revenue of $39.80 million during the quarter, compared to analysts’ expectations of $38.20 million. During the same period last year, the business earned $0.38 EPS. The business’s quarterly revenue was down 57.6% on a year-over-year basis. Analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Piper Sandler increased their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. HC Wainwright lowered their price objective on Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC dropped their price objective on Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Finally, JPMorgan Chase & Co. increased their price target on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $24.43.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP bought a new position in Day One Biopharmaceuticals in the 3rd quarter worth about $23,808,000. Alyeska Investment Group L.P. lifted its holdings in shares of Day One Biopharmaceuticals by 61.6% in the first quarter. Alyeska Investment Group L.P. now owns 4,059,764 shares of the company’s stock worth $32,194,000 after buying an additional 1,547,577 shares in the last quarter. AIGH Capital Management LLC bought a new position in shares of Day One Biopharmaceuticals in the third quarter valued at approximately $10,719,000. Mak Capital One LLC bought a new stake in Day One Biopharmaceuticals during the third quarter valued at $10,212,000. Finally, Balyasny Asset Management L.P. purchased a new position in Day One Biopharmaceuticals during the third quarter worth about $9,758,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.